JP2010524466A5 - - Google Patents

Download PDF

Info

Publication number
JP2010524466A5
JP2010524466A5 JP2010504124A JP2010504124A JP2010524466A5 JP 2010524466 A5 JP2010524466 A5 JP 2010524466A5 JP 2010504124 A JP2010504124 A JP 2010504124A JP 2010504124 A JP2010504124 A JP 2010504124A JP 2010524466 A5 JP2010524466 A5 JP 2010524466A5
Authority
JP
Japan
Prior art keywords
seq
sequence
cancer
antibody
human
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2010504124A
Other languages
English (en)
Japanese (ja)
Other versions
JP5209702B2 (ja
JP2010524466A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2008/005137 external-priority patent/WO2008130704A2/en
Publication of JP2010524466A publication Critical patent/JP2010524466A/ja
Publication of JP2010524466A5 publication Critical patent/JP2010524466A5/ja
Application granted granted Critical
Publication of JP5209702B2 publication Critical patent/JP5209702B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2010504124A 2007-04-17 2008-04-17 ＰＤＧＦＲβ特異的インヒビター Expired - Fee Related JP5209702B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US92397907P 2007-04-17 2007-04-17
US60/923,979 2007-04-17
PCT/US2008/005137 WO2008130704A2 (en) 2007-04-17 2008-04-17 PDGFRβ-SPECIFIC INHIBITORS

Publications (3)

Publication Number Publication Date
JP2010524466A JP2010524466A (ja) 2010-07-22
JP2010524466A5 true JP2010524466A5 (enExample) 2010-10-21
JP5209702B2 JP5209702B2 (ja) 2013-06-12

Family

ID=39837443

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2010504124A Expired - Fee Related JP5209702B2 (ja) 2007-04-17 2008-04-17 ＰＤＧＦＲβ特異的インヒビター

Country Status (14)

Country Link
US (3) US7740850B2 (enExample)
EP (1) EP2139921A2 (enExample)
JP (1) JP5209702B2 (enExample)
KR (1) KR101136262B1 (enExample)
CN (1) CN101707882A (enExample)
AU (1) AU2008242444B2 (enExample)
BR (1) BRPI0810374A2 (enExample)
CA (1) CA2682390A1 (enExample)
EA (1) EA019595B1 (enExample)
IL (1) IL200779A0 (enExample)
MX (1) MX2009011226A (enExample)
NZ (1) NZ579734A (enExample)
UA (1) UA99608C2 (enExample)
WO (1) WO2008130704A2 (enExample)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2604279A1 (en) 2008-03-27 2013-06-19 ZymoGenetics, Inc. Compositions and methods for inhibiting PDGFRBETA and VEGF-A
US20120231537A1 (en) * 2008-04-30 2012-09-13 Gradalis, Inc. Highly Pure Plasmid DNA Preparations
US8969068B2 (en) * 2008-04-30 2015-03-03 Gradalis, Inc. Processes for the preparation of highly pure plasmid compositions by enzymatic digestion of colanic acid
US20110305672A1 (en) 2008-07-25 2011-12-15 University Of Georgia Research Foundation, Inc. COMPOSITIONS FOR MESODERM DERIVED ISL1+ MULTIPOTENT CELLS (IMPs), EPICARDIAL PROGENITOR CELLS (EPCs) AND MULTIPOTENT CD56C CELLS (C56Cs) AND METHODS OF PRODUCING AND USING SAME
ES2410579T5 (es) 2008-12-16 2021-10-04 Novartis Ag Sistemas de despliegue de levaduras
TW201102068A (en) * 2009-06-02 2011-01-16 Novartis Ag Treatment of ophthalmologic disorders mediated by alpha-carbonic anhydrase isoforms
US8933037B2 (en) * 2009-09-28 2015-01-13 Medizinische Universitat Wien Methods involving PDGFRBETA inhibitors
WO2011075185A1 (en) 2009-12-18 2011-06-23 Oligasis Targeted drug phosphorylcholine polymer conjugates
ES2926988T3 (es) 2011-03-15 2022-10-31 X Body Inc Métodos de cribado de anticuerpos
CN102250249A (zh) * 2011-06-18 2011-11-23 常州亚当生物技术有限公司 一种抗VEGF/PDGFRbeta双特异性抗体及其应用
CA2843158A1 (en) 2011-08-26 2013-03-07 Merrimack Pharmaceuticals, Inc. Tandem fc bispecific antibodies
AU2012347972B2 (en) * 2011-12-05 2018-05-10 X-Body, Inc. PDGF receptor beta binding polypeptides
TWI613215B (zh) 2012-02-22 2018-02-01 再生元醫藥公司 抗－大－內皮素－１（ｂｉｇ－ｅｔ－１）抗體及其用途
JO3405B1 (ar) * 2013-01-09 2019-10-20 Regeneron Pharma الأجسام المضادة لمضاد مستقبل عامل النمو المشتق من الصفائح الدموية - بيتا واستخداماتها
HK1220465A1 (zh) 2013-03-06 2017-05-05 Merrimack Pharmaceuticals, Inc. 抗c-met串联fc双特异性抗体
WO2015035342A2 (en) 2013-09-08 2015-03-12 Oligasis Llc Factor viii zwitterionic polymer conjugates
US9914769B2 (en) 2014-07-15 2018-03-13 Kymab Limited Precision medicine for cholesterol treatment
DE202014010499U1 (de) 2013-12-17 2015-10-20 Kymab Limited Targeting von humaner PCSK9 zur Cholesterinbehandlung
KR102127408B1 (ko) * 2014-01-29 2020-06-29 삼성전자주식회사 항 Her3 scFv 단편 및 이를 포함하는 항 c-Met/항 Her3 이중 특이 항체
GB201403775D0 (en) 2014-03-04 2014-04-16 Kymab Ltd Antibodies, uses & methods
US9840553B2 (en) 2014-06-28 2017-12-12 Kodiak Sciences Inc. Dual PDGF/VEGF antagonists
KR20210013299A (ko) 2014-10-17 2021-02-03 코디악 사이언시스 인코포레이티드 부티릴콜린에스테라제 양성이온성 중합체 컨쥬게이트
CA2980385A1 (en) 2015-03-20 2016-09-29 Johann Wolfgang Goethe-Universitat Frankfurt Am Main Pericyte long non-coding rnas
ES2981791T3 (es) 2015-12-16 2024-10-10 Regeneron Pharma Composiciones y métodos para fabricar micropartículas de proteína
WO2017106609A2 (en) * 2015-12-16 2017-06-22 Kadmon Corporation, Llc. Pdgfr beta antibody
KR20250057128A (ko) 2015-12-30 2025-04-28 코디악 사이언시스 인코포레이티드 항체 및 이의 접합체
RU2769282C2 (ru) 2016-06-20 2022-03-30 Кимаб Лимитед Анти-PD-L1 и IL-2 цитокины
WO2018080812A1 (en) * 2016-10-30 2018-05-03 Henlix, Inc. Anti-pd-l1 antibodies and variants
EP3534947A1 (en) 2016-11-03 2019-09-11 Kymab Limited Antibodies, combinations comprising antibodies, biomarkers, uses & methods
US11440951B2 (en) 2017-03-13 2022-09-13 The Government Of The United States, As Represented By The Secretary Of The Army Therapeutic antibodies to Marburg virus
CN109021104B (zh) * 2017-06-12 2022-08-12 上海睿智化学研究有限公司 一种抗人血小板衍生生长因子β受体的抗体及其应用
WO2019165982A1 (en) * 2018-02-28 2019-09-06 WuXi Biologics Ireland Limited Monoclonal antibody against human lag-3, method for preparing same, and use thereof
EP3758737A4 (en) 2018-03-02 2022-10-12 Kodiak Sciences Inc. IL-6 ANTIBODIES AND FUSION CONSTRUCTS AND CONJUGATES THEREOF
DE102018204828A1 (de) 2018-03-29 2019-10-02 Ford Global Technologies, Llc Verhinderung von Glatteis durch Abwasser von Kraftfahrzeugen
WO2020029860A1 (zh) 2018-08-09 2020-02-13 北京智仁美博生物科技有限公司 针对狂犬病病毒的双特异性抗体及其用途
EP3868781A4 (en) * 2018-10-05 2022-07-06 Seoul National University R & DB Foundation PDGF RECEPTOR ANTIBODIES AND ITS USE
CA3157509A1 (en) 2019-10-10 2021-04-15 Kodiak Sciences Inc. Methods of treating an eye disorder
US20240174755A1 (en) * 2020-02-07 2024-05-30 Biorion Technologies B.V. Platelet derived growth factor receptor (pdgfr) antibodies, conjugates, compositions, and uses thereof
EP4724490A2 (en) 2023-06-12 2026-04-15 Amgen Inc. Lymphotoxin beta receptor agonist binding proteins
CN118440214B (zh) * 2024-04-02 2025-01-28 山东大学 一种靶向PDGFRβ的嵌合抗原受体、CAR-T细胞及应用

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5530101A (en) * 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
DK0584082T3 (da) 1991-01-31 2000-10-16 Univ California Domæner i den ekstracellulære region af humane blodpladeafledte vækstfaktorreceptorpolypeptider
PT1024191E (pt) 1991-12-02 2008-12-22 Medical Res Council Produção de auto-anticorpos a partir de reportórios de segmentos de anticorpo e exibidos em fagos
US20020009443A1 (en) * 1991-12-02 2002-01-24 Vanitha Ramakrishman Inhibitory immunoglobulin polypeptides to human pdgf beta receptor
US5817310A (en) * 1991-12-02 1998-10-06 Cor Therapeutics, Inc. Inhibitory immunoglobulin polypeptides to human PDGF beta receptor
US5620687A (en) 1993-02-25 1997-04-15 Zymogenetics, Inc. Inhibition of intimal hyperplasia using antibodies to PDGF beta receptors
US5976534A (en) 1993-02-25 1999-11-02 Zymogenetics, Inc. Inhibition of intimal hyperplasia using antibodies to PDGF receptors and heparin
US5840299A (en) * 1994-01-25 1998-11-24 Athena Neurosciences, Inc. Humanized antibodies against leukocyte adhesion molecule VLA-4
US6811779B2 (en) * 1994-02-10 2004-11-02 Imclone Systems Incorporated Methods for reducing tumor growth with VEGF receptor antibody combined with radiation and chemotherapy
US5882644A (en) 1996-03-22 1999-03-16 Protein Design Labs, Inc. Monoclonal antibodies specific for the platelet derived growth factor β receptor and methods of use thereof
US6259971B1 (en) * 1997-06-30 2001-07-10 Compaq Computer Corporation Portable fuel-cell-powered system with ultrasonic atomization of H2O by-product
US7740841B1 (en) * 2000-01-28 2010-06-22 Sunnybrook Health Science Center Therapeutic method for reducing angiogenesis
CA2409991A1 (en) 2000-05-24 2001-11-29 Imclone Systems Incorporated Bispecific immunoglobulin-like antigen binding proteins and method of production
CA2424184A1 (en) * 2000-09-22 2003-03-20 Siemens Aktiengesellschaft Method for monitoring the discharge of media out of a fuel cell, and a fuel cell system
EP1313161A1 (en) * 2001-11-15 2003-05-21 Ballard Power Systems AG Fuel cell system and method for operating the same
US7582726B2 (en) * 2003-11-10 2009-09-01 Ghc Research Development Corporation VEGF receptor antagonists
EP1786918A4 (en) 2004-07-17 2009-02-11 Imclone Systems Inc NEW BISPECIFIC ANTIBODY TETRAVALENT
WO2008011216A2 (en) 2006-05-16 2008-01-24 Pro-Pharmaceuticals, Inc. Galactose-pronged polysaccharides in a formulation for antifibrotic therapies

Similar Documents

Publication Publication Date Title
JP2010524466A5 (enExample)
IL261585A (en) Antigen-binding human proteins that bind beta-klotho, fgf receptors and their complexes
JP2012505912A5 (enExample)
NZ610153A (en) Novel anti-dr5 antibody
AU2018256487A1 (en) Antibodies that bind to TL1A and their uses
NZ603972A (en) Anti-fgfr2 antibodies
PE20140133A1 (es) Nuevas proteinas de union a antigenos
JP2015522252A5 (enExample)
JP2020500538A5 (enExample)
PH12014500089A1 (en) Antibodies that bind to ox40 and their uses
NZ602892A (en) Antibodies that bind human cd27 and uses thereof
RU2015129813A (ru) Антитела, которые связываются с лигандом запрограммированной клеточной смерти 1 (pd-l1)
WO2012045481A8 (en) Antibody targeting osteoclast-related protein siglec-15
MX2011008843A (es) Anticuerpos humanizados que se unen a cd19 y sus usos.
RU2015126533A (ru) Анти-cd47 антитела и способы их применения
EA032189B9 (ru) Изолированные человеческие моноклональные антитела против ингибитора пути тканевого фактора (tfpi) и фармацевтическая композиция, содержащая их
JP2009106306A5 (ja) 抗PDGFRα抗体
RU2013140625A (ru) Антитела против ангиопоэтина-2 человека
RU2016119152A (ru) Стабильные и растворимые антитела, ингибирующие vegf
IL198379A (en) Human antibodies and antibodies that bind sphingosine-1-phosphate, their encoded nucleic acids, and their preparations and methods for treating the disease
JP2013529183A5 (enExample)
NZ709390A (en) Folate receptor 1 antibodies and immunoconjugates and uses thereof
AR080698A1 (es) Anticuerpo o fragmento del mismo que especificamente enlaza la variante de csf -1r humano, composicion farmaceutica que lo comprende, su uso para la manufactura de un medicamento util para el tratamiento de cancer y metodo para determinar si un sujeto es candidato para tratamiento de cancer basado e
NZ584726A (en) Heparin-binding epidermal growth factor-like growth factor antigen binding proteins
JP2012507294A5 (enExample)